ArticleInternational journal of colorectal disease2008
Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases.
Article in International journal of colorectal disease, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- The role of faecal calprotectin in diagnosis and staging of colorectal neoplasia: a systematic review and meta-analysis.BMC gastroenterology · 2022Pooled it
- Comparison of faecal protein biomarkers' diagnostic accuracy for colorectal advanced neoplasms: a systematic review and meta-analysis.Scientific reports · 2022Pooled it
- Faecal calprotectin to detect inflammatory bowel disease: a systematic review and exploratory meta-analysis of test accuracy.BMJ open · 2019Pooled it
- Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis.BMJ (Clinical research ed.) · 2010Pooled it
- Assessment of complementary feeding of Canadian infants: effects on microbiome & oxidative stress, a randomized controlled trial.BMC pediatrics · 2017Trial
- Biosensor-Based Detection of Calprotectin and Lactoferrin as Neutrophil-Derived Markers of Inflammatory Bowel Diseases: From Molecular Pathophysiology to Point-of-Care Platforms.International journal of molecular sciences · 2026Review
- Research progress on the diagnostic value of fecal calprotectin in colorectal tumors.Frontiers in medicine · 2025Review
- Diagnostic value of fecal calprotectin in primary care patients with gastrointestinal symptoms: A retrospective Swedish cohort study.JGH open : an open access journal of gastroenterology and hepatology · 2023Article
- Review
- Pre-and post-treatment evaluation of intestinal inflammation inJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2021Article
- International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.United European gastroenterology journal · 2021Article
- Article
- Faecal Calprotectin.The Clinical biochemist. Reviews · 2018Review
- Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.Digestive diseases and sciences · 2017Article
- Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.Journal of gastroenterology · 2016Review
- Calprotectin could be a potential biomarker for acute appendicitis.Journal of translational medicine · 2016Article
- Improving the Preoperative Diagnostic Accuracy of Acute Appendicitis. Can Fecal Calprotectin Be Helpful?PloS one · 2016Article
- Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists.Digestive diseases and sciences · 2015Article
- Point-of-care testing in the diagnosis of gastrointestinal cancers: current technology and future directions.World journal of gastroenterology · 2015Review
- Faecal calprotectin for differentiating between irritable bowel syndrome and inflammatory bowel disease: a useful screen in daily gastroenterology practice.Frontline gastroenterology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsObjective of this study was to compare the assay characteristics of a new fecal calprotectin rapid test with an enzyme-linked immunosorbent assay (ELISA). The second aim was to assess the potential of measuring fecal calprotectin as screening method for intestinal inflammation and colorectal malignancies. PATIENTS AND
methodsOne hundred forty patients with lower gastrointestinal symptoms referred to colonoscopy provided fecal samples (56, control group; 18, diverticulosis; 29, colorectal adenoma; 8, colorectal carcinoma (CRC); 18, active inflammatory bowel disease (IBD); 11, intestinal infections). Feces were analyzed by two assay methods.
resultsCompared to the control group (median 25.8 microg/g), calprotectin levels were significantly increased in adenoma (66.3 microg/g), CRC (164 microg/g), intestinal infections (306 microg/g), and active IBD (797 microg/g). An adequate diagnostic accuracy could be found for active IBD with a sensitivity, specificity, and an area under the curve (AUC) of 100%, 79%, and 0.955 (ELISA) vs. 89%, 80%, and 0.896 (rapid test). Similar results were obtained for CRC (100%, 79%, 0.922 vs. 100%, 80%, 0.948) whereas in adenomas a low sensitivity, specificity, and AUC of 55%, 79%, and 0.686 vs. 52%, 80%, and 0.666 were found for fecal calprotectin.
conclusionsBoth fecal calprotectin assays are effective in identifying active IBD and CRC but lack analytical sensitivity in separating CRC from adenoma as well as adenoma from the control group. The new calprotectin rapid test is a convenient method for assessing the calprotectin level in an outpatient setting. Henceforth, it provides a precondition for the fecal calprotectin method to challenge fecal occult blood testing in further evaluations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.